Hospira Drug-Making Facility In Quality-Control Violations, U.S. FDA Says
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA warned Hospira its India facility for producing finished drugs has significant quality-manufacturing violations that could cause contamination.